Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

KO.NYSE

Coca-Cola

Consumer Defensive | Beverages - Non-Alcoholic

Global beverage company with brands including Coca-Cola, serving consumers through sparkling drinks, juices, water, and other beverages.

Flagship Insight

Why This Defensive Consumer Giant Faces Severe Valuation Pressure Despite Record Margins

A sharp divergence exists regarding this asset's valuation sustainability. While high consensus supports its robust pricing power and asset-light model as defensive shields, rising packaging costs, restrictive monetary policy, and emerging pharmaceutical appetite suppressants present severe headwinds, threatening to compress its premium multiple over the forecast horizon.

Forecast TimelineUpdated On Jul 02 2026

Coca-Cola (KO) Stock Forecast and AI Rating

Recommendation

Hold & Monitor

Model signals are balanced; wait for clearer evidence.

2027

1-Year

NEUTRAL

$84

-0.4%

+4.2% IF INCL. DIVS

2029

3-Year

N/A

$92

+11.9%

2031

5-Year

NEUTRAL

$101

+19.7%

+36% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The base-case outlook for this defensive staple reflects a structural conflict between exceptional operational execution and severe valuation gravity. While the asset-light franchise model successfully insulates core margins from direct supply chain shocks, a restrictive macroeconomic regime characterized by elevated risk-free yields and persistent currency translation headwinds will exert downward pressure on the asset's premium multiple. Over the five-year horizon, the business will continue to compound intrinsic value, but multiple compression will limit the translation of operational success into equivalent stock price appreciation.

Key insights

The asset-light concentrate model effectively externalizes capital expenditures and physical inflation risks to bottling partners, protecting parent margins.
Restrictive central bank policy maintains elevated discount rates, compressing the equity risk premium and challenging the asset's premium valuation.
Emerging pharmaceutical appetite suppressants pose a long-term structural threat to volumetric growth in developed markets, capping long-term expansion.
Persistent currency translation headwinds from a strong domestic currency will continue to suppress reported international earnings and revenue growth.
A massive off-balance-sheet tax liability represents a significant binary risk that could severely impact future cash flows and debt leverage.
Total returns will rely heavily on dividend yield and share repurchases rather than capital appreciation, underperforming on a risk-adjusted basis.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Coca-Cola quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Coca-Cola.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$80.77	$82.95	$85.82	$736.09
Quarter 2+6M	Jan 02, 2027	$78.35	$82.90	$88.40	$724.14
Quarter 3+9M	Apr 02, 2027	$76.78	$82.56	$87.51	$713.57
Quarter 4+1Y	Jul 02, 2027	$76.02	$83.68	$90.14	$723.38
Quarter 5+15M	Oct 02, 2027	$72.22	$83.77	$91.00	$716.61
Quarter 6+18M	Jan 02, 2028	$70.77	$84.17	$93.73	$738.34
Quarter 7+21M	Apr 02, 2028	$70.77	$85.59	$95.60	$746.91
Quarter 8+2Y	Jul 02, 2028	$68.65	$87.03	$98.47	$771.93
Quarter 9+27M	Oct 02, 2028	$65.90	$86.67	$97.48	$782.73
Quarter 10+30M	Jan 02, 2029	$64.58	$88.20	$101.38	$807.31
Quarter 11+33M	Apr 02, 2029	$63.94	$89.79	$104.42	$822.72
Quarter 12+3Y	Jul 02, 2029	$62.02	$90.78	$106.51	$846.10
Quarter 13+39M	Oct 02, 2029	$59.54	$91.68	$108.64	$852.53
Quarter 14+42M	Jan 02, 2030	$59.54	$93.08	$111.90	$882.91
Quarter 15+45M	Apr 02, 2030	$58.35	$94.33	$114.14	$900.46
Quarter 16+4Y	Jul 02, 2030	$56.60	$95.77	$117.56	$922.67
Quarter 17+51M	Oct 02, 2030	$55.47	$95.90	$118.74	$935.91
Quarter 18+54M	Jan 02, 2031	$54.91	$97.99	$123.49	$952.30
Quarter 19+57M	Apr 02, 2031	$53.81	$99.29	$125.96	$976.28
Quarter 20+5Y	Jul 02, 2031	$52.74	$100.68	$129.74	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's failure to reconcile peak-cycle pricing power with a structurally altered macroeconomic and technological regime. While the crowd celebrates the parent company's asset-light model, they overlook the severe margin compression occurring within the subordinate bottling network due to packaging and energy inflation. Furthermore, the market is ignoring the mathematical reality of valuation duration risk; a premium multiple is highly fragile against structurally elevated risk-free yields. Additionally, the crowd systematically underestimates the long-term threat of pharmaceutical appetite suppressants on volumetric demand, alongside a massive, unreserved off-balance-sheet tax liability. This mismatch between high-multiple pricing and structural growth limitations creates a significant risk of multiple compression.

Advisor Disagreement

The primary disagreement across the reports centers on the severity of multiple compression versus the durability of the company's pricing power. Some perspectives argue that the premium valuation is completely unsustainable in a high-rate environment and will trigger a significant price correction. Others contend that the asset's unassailable brand moat and structural insulation from physical inflation justify a permanent quality premium, shielding it from severe drawdowns. Additionally, there is disagreement regarding the speed and impact of weight-loss drug adoption on long-term volume trends.

Financial Reviews by iPulse AI

Earnings and financials

Recent financial results show very strong profit growth, with operating income rising significantly. The company has been highly successful at raising prices to boost its earnings, even as actual sales volumes remain flat. However, there is a clear disagreement about whether this profit growth can continue. Some analysts warn that the company has reached the limit of its pricing power, and that future earnings will slow down as consumers refuse to pay more. Additionally, a strong dollar is making international profits look smaller when converted back to domestic currency. While the company's cash flow remains incredibly strong and easily supports its dividend, future earnings growth will likely be much slower and more dependent on financial engineering rather than selling more drinks.

Profitability and margins

The company boasts spectacular profit margins, with gross margins holding steady above sixty percent and operating margins reaching record highs. This profitability is driven by the company's incredible brand power, which allows it to pass rising costs directly to consumers. However, there is a sharp clash over whether these high margins are sustainable. Some experts believe margins have peaked and must eventually shrink due to rising packaging costs and the need to support struggling bottling partners. Others argue that the company's intellectual property model will permanently protect its high profitability. While the company remains far more profitable than its competitors, paying a premium price for the stock leaves no room for error if margins begin to slip even slightly.

Balance sheet and leverage

The company's balance sheet is widely considered a financial fortress, offering excellent safety for investors. With low debt leverage and strong cash reserves, the company easily covers its interest payments and faces no risk of financial distress, even with high interest rates. This financial strength guarantees that its long dividend-paying streak remains safe. However, there is a major point of concern regarding a massive, unresolved tax dispute with the government. If the company loses this legal battle, it could be forced to pay billions of dollars, which would require taking on significant new debt. While the day-to-day financial health of the company is incredibly secure, this large tax risk limits its ability to make major new investments or buybacks.

Capex and investment intensity

The company operates a highly efficient, low-spending business model. By letting independent bottling partners handle the expensive physical work of manufacturing and shipping, the parent company keeps its own capital spending extremely low, at around four percent of revenue. This low investment intensity is a major advantage during times of high interest rates, as it frees up massive amounts of cash to pay dividends and buy back stock. However, opinions differ on the long-term risks of this strategy. Some warn that if bottling partners are squeezed by inflation and underinvest in their own facilities, the entire distribution system could suffer. Overall, the low capital spending is a powerful defensive shield, but it offers limited opportunities for aggressive, high-growth expansion.